Catalyst Wire Dossier Catalyst Wire Dossier

ABI-007 (Abraxane)

paclitaxel protein-bound particles for injectable suspension · Celgene
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ABI-007 (Abraxane), covering 2012-03-13 to 2012-03-13. Get the full timeline:

Most recent: Clinical Trial Update: Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer [Phase 2]

See pricing